NEUROD6

Across TCGA pan-cancer cohorts, NEUROD6 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated NEUROD6 data layer compared with 5 for mutation status.

The strongest signal is observed in thyroid carcinoma (THCA), where higher NEUROD6 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated NEUROD6 expression acts as an unfavorable survival marker, although some lineages such as LGG and ESCA show a favorable association.

THCA, ACC, and PAAD are the cancer types where NEUROD6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Tertile	III,IV	0.158	0.748	.002	42	view →
ACC	DFS	Tertile	All	0.068	0.667	.005	36	view →
PAAD	OS	Tertile	All	0.011	0.641	<.001	36	view →
LUAD	OS	Tertile	All	0.658	0.847	.002	30	view →
LGG	OS	Tertile	All	0.928	0.812	.005	29	view →
COAD	OS	Tertile	IV	0.039	0.660	<.001	27	view →
ESCA	OS	Tertile	III,IV	0.669	0.349	.017	24	view →
SKCM	DFS	Tertile	All	0.199	0.640	.009	18	view →
LAML	DFS	Tertile	All	0.160	0.591	.001	18	view →
PCPG	OS	Tertile	All	0.516	0.947	.023	18	view →
KIRC	DFS	Tertile	All	0.620	0.801	.029	12	view →
LUSC	OS	Tertile	All	0.201	0.660	.049	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

NEUROD6–THCA (DFS)

Open the THCA breakdown →